Evidence map›Paper›PMID 40350086›Full record

Trial reportOphthalmology2025

Randomized Noninferiority Trial of Direct Selective Laser Trabeculoplasty in Open-Angle Glaucoma and Ocular Hypertension: GLAUrious Study.

Gus Gazzard, Nathan Congdon, Augusto Azuara-Blanco, Eytan Z Blumenthal, Ketevan Gomelauri, Monika Zaliniyan, Carlo E Traverso, Zohar Bracha, Ana Dvalishvili, Yoram Solberg and 3 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled TrialEquivalence Trial
PubMed Publisher
In one paragraph

Trial report in Ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03750201 (Direct Selective Laser Trabeculoplasty), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03750201 nacompletednot on this map

Direct Selective Laser Trabeculoplasty (DSLT) In Open Angle Glaucoma (POAG): A Randomized Controlled Trial

TypeinterventionalSponsorBelkinVisionRan2018 to 2022Enrolled201ConditionsOpen Angle Glaucoma, Ocular HypertensionArmsDirect Selective Trabeculoplasty, Selective Trabeculoplasty
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Gus GazzardNIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom. Electronic address: g.gazzard@nhs.net.
Nathan CongdonCentre for Public Health, Queen's University Belfast, Belfast, United Kingdom; Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China; Orbis International, New York, New York.
Augusto Azuara-BlancoCentre for Public Health, Queen's University Belfast, Belfast, United Kingdom.
Eytan Z BlumenthalDepartment of Ophthalmology, Rambam Health Care Campus, Haifa, Israel; Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
Ketevan GomelauriJavrishvili Eye Clinic Oftalmij, Tbilisi, Georgia.
Monika ZaliniyanAkhali Mzera Eye Clinic, Tbilisi, Georgia.
Carlo E TraversoClinica Oculistica, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili, University of Genova, Policlinico Ospedale San Martino IRCCS, Genova, Italy.
Zohar BrachaShaare Zedek Medical Center, Jerusalem, Israel.
Ana DvalishviliNew Vision University, Tbilisi, Georgia.
Yoram SolbergBELKIN Vision Ltd., Yavne, Israel.
Michael BelkinBELKIN Vision Ltd., Yavne, Israel; Goldschleger Eye Research Institute, Tel Aviv University, Sheba Medical Centre, Tel Hashomer, Israel.
Thomas W SamuelsonMinnesota Eye Consultants and University of Minnesota, Minneapolis, Minnesota.
GLAUrious Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEffective glaucoma treatment is limited by nonadherence to medications and access to selective laser trabeculoplasty (SLT). The GLAUrious study compared automated, gonioscopy-free, noncontact, image-guided direct selective laser trabeculoplasty (DSLT) with conventional SLT in open-angle glaucoma (OAG) and ocular hypertension (OHT) to reduce intraocular pressure (IOP).

designProspective, multicenter, randomized, controlled, evaluator-masked noninferiority trial.

participantsParticipants aged ≥ 40 years with OAG or OHT, on 0-3 hypotensive medications at screening, and washout IOP of 22-35 mmHg at 14 centers.

methodsAfter washout, 192 participants randomized 1:1 to DSLT (n = 99) or SLT (n = 93). Intraocular pressure was assessed before treatment and through 12 months after the procedure, with washout IOP at baseline and 6 months.

main outcome measuresDifference between DSLT and SLT in mean IOP change from baseline to 6 months (noninferiority margin, -1.95 mmHg). Exploratory efficacy and safety outcomes were assessed over 12 months.

resultsOf 156 participants (81.3%) without major protocol deviations analyzed at 6 months, the mean ± standard error (SE) washout IOP reduction from baseline was 5.5 ± 0.5 mmHg (-20.6%) after DSLT and 6.2 ± 0.5 mmHg (-23.6%) after SLT. The between-group difference (SLT-DSLT) in mean IOP reduction was -0.7 mmHg (95% confidence interval [CI], -2.2 to 0.8 mmHg; P = 0.09 [not significant] for noninferiority). Of 161 participants (83.9%) without major protocol deviations analyzed at 12 months, mean ± SE nonwashout IOP reduction from screening was 3.2 ± 0.4 mmHg (-12.2%) after DSLT and 3.2 ± 0.4 mmHg (-9.4%) after SLT. The between-group difference in mean IOP reduction was 0.01 mmHg (95% CI, -1.1 to 1.1 mmHg; P < 0.001 for noninferiority). Safety profiles were similar between groups, although clinically nonsignificant punctate subconjunctival hemorrhage was more frequent in the DSLT group. Ocular AEs generally were mild and resolved without intervention.

conclusionsThe 6-month primary end point did not achieve statistical noninferiority compared with conventional SLT. Nonetheless, DSLT was well tolerated and provided an effective reduction in IOP that was sustained for 12 months. Failure to demonstrate noninferiority does not prove inferiority; DSLT remains an effective option in the early treatment paradigm and can be considered as a first-line treatment when SLT is not readily accessible. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

Glaucoma, Open-AngleIntraocular PressureLaser TherapyOcular HypertensionTrabeculectomyAdultAgedFemaleGonioscopyHumansMaleMiddle AgedProspective StudiesTonometry, OcularTreatment OutcomeVisual AcuityDirect selective laser trabeculoplastyIntraocular pressureOcular hypertensionOpen-angle glaucomaSelective laser trabeculoplasty

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.